CAT Where from Here

Tipped for the New Year in the Times today, I've been watching but not buying for about two weeks. Looking a very interesting bet!


Completing the picture is Cambridge Antibody Technology. This is a biotech company, specialising in genomics, whose shares are lolling around near five-year lows. All sorts of biotechs have fallen from favour in recent years and CAT’s woe was deepened when David Chiswell, the founder and chief executive, resigned unexpectedly in April. But this event has not, as some feared, been succeeded by anything more troubling, and under the stewardship of Peter Chambre, CAT looks set to capitalise on its past achievements.